Literature DB >> 22370836

Drug resistance of Mycobacterium tuberculosis strains in southern Brazil.

Laynara Katize Grutzmacher1, Eduardo Monguilhott Dalmarco, Solange Lucia Blatt, Caio Mauricio Mendes de Cordova.   

Abstract

INTRODUCTION: The aim of this work was to evaluate the prevalence of Mycobacterium tuberculosis (MT) strains with mutations that could result in resistance to the main drugs used in treatment in a region with one of the highest numbers of tuberculosis (TB) cases in southern Brazil.
METHODS: Deoxyribonucleic acid (DNA) from 120 sputum samples from different patients suspicious of pulmonary tuberculosis who attended the Municipal Public Laboratory for Mycobacterium sp. diagnosis was directly amplified and analyzed by PCR-SSCP. The DNA was amplified in known hotspot mutation regions of the genes rpoB, ahpC, embB, katG, inhA, and pncA.
RESULTS: The percentage of samples positive by culture was 9.2% (11/120); 5% (6/120) were positive by bacilloscopy and MT-PCR, and DNA fragments of the aforementioned resistance genes could be amplified from seven (7) of the eleven (11) samples with positive results, either by culture or PCR/bacilloscopy. All presented a SSCP pattern similar to a native, nonresistant genotype, with the ATCC strain 25177 as control, except for one sample (0.01%), which presented a SSCP profile demonstrating mutation at the embB gene.
CONCLUSIONS: These results are consistent with the empirical observations by physicians treating TB patients in our region of a low occurrence of cases that are refractory to conventional treatment schemes, in contrast to other parts of the country. Continued surveillance, especially molecular, is essential to detect and monitor the outbreak of MT-resistant strains.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370836     DOI: 10.1590/s0037-86822012000100018

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

1.  Rapid detection of MDR-Mycobacterium tuberculosis using modified PCR-SSCP from clinical Specimens.

Authors:  Imani Fooladi Abbas Ali; Farzam Babak; Mousavi Seyed Fazlollah; Jonaidi Jafari Nematollah
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

2.  Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study).

Authors:  Izabella Picinin Safe; Marcus Vinícius Guimarães Lacerda; Vitoria Silva Printes; Adriana Ferreira Praia Marins; Amanda Lia Rebelo Rabelo; Amanda Araújo Costa; Michel Araújo Tavares; Jaquelane Silva Jesus; Alexandra Brito Souza; Francisco Beraldi-Magalhães; Cynthia Pessoa Neves; Wuelton Marcelo Monteiro; Vanderson Souza Sampaio; Eduardo P Amaral; Renata Spener Gomes; Bruno B Andrade; Marcelo Cordeiro-Santos
Journal:  PLoS One       Date:  2020-06-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.